Adagene (ADAG)
NASDAQ:ADAG
Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.82
-$0.15(-7.28%)
At close: 4:00 PM EST
$3.82
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $4.75
Previous CloseN/A
Volume1.51K
Average Volume (3M)336.37K
Market Cap
$181.01M
Enterprise Value$76.69M
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Sep 02, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding47,406,593
10 Day Avg. Volume497,669
30 Day Avg. Volume336,374
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue9.97
Enterprise Value/Gross Profit10.79
Enterprise Value/Ebitda-4.17
Forecast
1Y Price Target
$8.33Price Target Upside118.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Dose ResponseADG126 (muzastotug) demonstrated a clear dose‑response with higher dosing producing better and more durable tumor responses, supporting potential best‑in‑class efficacy in its target indications.
Regulatory Clarity And Approval PathwayFDA alignment on Phase 2 and Phase 3 trial designs combined with Fast Track designation and plans to pursue accelerated approval based on tumor response reduce regulatory uncertainty and improve the prospect of an efficient approval path.
Strategic Collaborations And External ValidationInvestment from a major pharma partner and collaborations, including combination studies with PD‑1 agents and a partnership with Roche, provide external validation and broaden development options that could enhance clinical activity.
Bears Say
Capital Raise And Shareholder ImpactThe prospect of raising additional capital raises the likelihood of equity dilution and could put downward pressure on the stock and existing shareholder value.
Financing Need And Execution RiskCash reserves are limited relative to ongoing spending, creating a material need for additional financing that elevates execution risk for ongoing development plans.
Operational Risk From High BurnHigh cash burn combined with limited reserves increases the risk that clinical programs may face delays or scaling back if new funding is not secured.
Adagene News
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.30 and its highest was $4.75 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $181.01M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Sep 02, 2026 which is in 138 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.22.
How many shares outstanding does Adagene have?
Adagene has 47,406,593 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (118.06% Upside)
$8.33 (118.06% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.75%
12-Months-Change
Fundamentals
Return on Equity
-48.20%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$8.33
▲(118.06% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
6.14% Other Institutional Investors
93.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---